Search

Your search keyword '"Meier JJ"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Meier JJ" Remove constraint Author: "Meier JJ" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
18 results on '"Meier JJ"'

Search Results

1. Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.

2. Increased incidence of GERD in GLP-1 treated patients: fact or artefact?

3. Microbiome composition and central serotonergic activity in patients with depression and type 1 diabetes.

4. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.

5. Prospective External Validation of an Algorithm Predicting Hourly Basal Insulin Infusion Rates from Characteristics of Patients with Type 1 Diabetes Treated with Insulin Pumps.

6. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.

7. Digestive, Anorectal, and Urogenital Functions in Patients with Type 2 Diabetes Mellitus, Impaired Glucose Tolerance and Normal Glucose Tolerance: Association with Autonomic Neuropathy.

9. Comparison of Insulin-Treated Patients with Ambiguous Diabetes Type with Definite Type 1 and Type 2 Diabetes Mellitus Subjects: A Clinical Perspective.

10. Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review.

11. Measurement of Gastric Emptying Using a 13C-octanoic Acid Breath Test with Wagner-Nelson Analysis and Scintigraphy in Type 2 Diabetes.

12. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.

13. Gut microbiota differs in composition between adults with type 1 diabetes with or without depression and healthy control participants: a case-control study.

14. Digital Responsibility Goals - A Framework for a Human-Centered Sustainable Digital Economy with a Focus on Trusted Digital Solutions.

15. Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment.

16. Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.

17. The incretin/glucagon system as a target for pharmacotherapy of obesity.

18. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.

Catalog

Books, media, physical & digital resources